TYK2 and psoriasis vulgaris: In conclusion, this analysis provides additional support that deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, has an acceptable safety and tolerability profile and provides durable efficacy through 3 years in Japanese patients with plaque psoriasis.